Procurement contracts for COVID-19 vaccines
During the COVID-19 pandemic, the federal government procured vaccines from different manufacturers at an early stage to protect the public. It was therefore able to secure rapid access to effective COVID-19 vaccines for people in Switzerland. It focused on mRNA vaccines, supplemented with other vaccines.
Federal Administrative Court’s judgment
Following appeals regarding the publication of contracts with Moderna and Novavax, the Federal Administrative Court ruled on 10 February 2026 that the contracts must be disclosed in unredacted form. These judgments became legally binding at the beginning of April 2026. The relevant contracts are therefore being fully disclosed.
See Procurement of COVID-19 vaccines (in German).
General information
The contracts on the procurement of COVID-19 vaccines are disclosed in line with the requirements of the Federal Act on Freedom of Information in the Administration (FoIA).
All contracts and agreements are drafted in English and are therefore only available in English.
Published contractual documents (unredacted) concerning Moderna and Novavax
Please note: personal data remains redacted in all documents.
Moderna Switzerland GmbH
Novavax Inc. USA
Contractual documents relating to other manufacturers
The following contracts on the procurement of COVID-19 vaccines with other manufacturers were disclosed in 2021 in line with the requirements of the Federal Act on Freedom of Information in the Administration (FoIA) in partly redacted form (protection of manufacturers’ business or manufacturing secrets).
Pfizer AG
Janssen Pharmaceutica NV
AstraZeneca AG
CureVac Corporate Services GmbH
Federal Office of Public Health FOPH
Schwarzenburgstrasse 157
Switzerland - 3003 Bern